Cardiac troponins provide useful information for estimating infarct size and early risk assessment in patients with acute myocardial infarction, complementary to cardiac function and volumes.
Does cardiac troponin measurement accurately estimate infarct size and aid in risk stratification in patients with acute myocardial infarction?
Cardiac troponin levels can serve as a useful surrogate for estimating infarct size and aiding early risk stratification in patients with acute myocardial infarction, particularly STEMI.
In acute myocardial infarction (AMI), the extent of myocardial damage is closely linked to prognosis. Early determination of infarct size is therefore key to assessing the future risk of patients and instructive for optimization of therapeutic strategies. The cardiac troponins, by allowing the physician to track the extent of injury suffered by the myocardium, provide a window into the heart. This article addresses the relationship between the cardiac troponins and the infarct size in AMI. Taken together, the data suggest that the cardiac troponins provide very useful information in this respect and especially in patients with ST elevation myocardial infarction. More studies are needed to understand how cardiac troponin-estimated infarct size may be integrated with other prognostic assessments and employed systematically in risk stratification. Early data are promising and indicate that cardiac troponins could provide useful information for early risk assessment that is complementary to the determination of cardiac function and volumes.
Jonas Hallén (Sun,) conducted a review in Acute myocardial infarction. Cardiac troponins was evaluated. Cardiac troponins provide useful information for estimating infarct size and early risk assessment in patients with acute myocardial infarction, complementary to cardiac function and volumes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: